Published in Curr Drug Targets on October 01, 2013
Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients. Neuropsychopharmacology (2014) 0.85
Current status of fluid biomarkers in mild traumatic brain injury. Exp Neurol (2015) 0.82
First evidence for glial pathology in late life minor depression: S100B is increased in males with minor depression. Front Cell Neurosci (2015) 0.78
6-OHDA-Induced Changes in Parkinson`s Disease-Related Gene Expression are not Affected by the Overexpression of PGAM5 in In Vitro Differentiated Embryonic Mesencephalic Cells. Cell Mol Neurobiol (2015) 0.78
Serum S100B Is Related to Illness Duration and Clinical Symptoms in Schizophrenia-A Meta-Regression Analysis. Front Cell Neurosci (2016) 0.76
S100B blood levels and childhood trauma in adolescent inpatients. J Psychiatr Res (2014) 0.76
Venlafaxine ameliorates the depression-like behaviors and hippocampal S100B expression in a rat depression model. Behav Brain Funct (2016) 0.75
A new bioinformatic insight into the associated proteins in psychiatric disorders. Springerplus (2016) 0.75
An Interplay of S-Nitrosylation and Metal Ion Binding for Astrocytic S100B Protein. PLoS One (2016) 0.75
Serum S100B Protein is Specifically Related to White Matter Changes in Schizophrenia. Front Cell Neurosci (2016) 0.75
Serum proteins mediate depression's association with dementia. PLoS One (2017) 0.75
Serum S100B Protein Levels in Patients with Panic Disorder: Effect of Treatment with Selective Serotonine Reuptake Inhibitors. Psychiatry Investig (2014) 0.75
S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression. Int J Neuropsychopharmacol (2015) 0.75
Comparative proteome analysis for identification of differentially abundant proteins in SIDS. Int J Legal Med (2017) 0.75
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (2003) 16.14
Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia. Neuroimage (2003) 8.47
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry (1999) 5.63
S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol (2001) 5.29
The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci (1996) 4.63
Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology (2007) 4.38
Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A (1998) 4.16
Alterations in 5-HT1B receptor function by p11 in depression-like states. Science (2006) 3.55
The S100 protein family: history, function, and expression. Brain Res Bull (1995) 3.16
miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science (2010) 2.75
Calcium-dependent and -independent interactions of the S100 protein family. Biochem J (2006) 2.62
Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry (2001) 2.55
Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res (2004) 2.54
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A (2011) 2.37
Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets (2007) 2.26
Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry (2000) 2.21
Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry (2008) 2.14
Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med (2010) 2.09
The Allen Brain Atlas: 5 years and beyond. Nat Rev Neurosci (2009) 2.00
Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta (2001) 1.99
Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull (2001) 1.86
Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull (2001) 1.83
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry (2004) 1.82
Astrocytic neurotransmitter receptors in situ and in vivo. Prog Neurobiol (1997) 1.76
Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry (2000) 1.71
Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry (2000) 1.68
Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology (2005) 1.65
Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci (2003) 1.61
Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res (2002) 1.56
Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci (2003) 1.56
S100B expression defines a state in which GFAP-expressing cells lose their neural stem cell potential and acquire a more mature developmental stage. Glia (2007) 1.54
Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer (2003) 1.50
Mapping the depressed brain: a meta-analysis of structural and functional alterations in major depressive disorder. J Affect Disord (2011) 1.49
Enhanced hippocampal neurogenesis by intraventricular S100B infusion is associated with improved cognitive recovery after traumatic brain injury. J Neurotrauma (2005) 1.46
Postoperative course of S-100B protein and neuron-specific enolase in patients after implantation of continuous and pulsatile flow LVADs. J Heart Lung Transplant (2001) 1.45
Identification of the cortical neurons that mediate antidepressant responses. Cell (2012) 1.42
Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci (2007) 1.40
Peripheral markers of blood-brain barrier damage. Clin Chim Acta (2004) 1.39
Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry (2000) 1.38
Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology (2004) 1.36
Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett (2007) 1.35
Cholinergic interneurons in the nucleus accumbens regulate depression-like behavior. Proc Natl Acad Sci U S A (2012) 1.33
The neuropathology of primary mood disorder. Brain (2002) 1.32
Sex-dependent influences of obesity on cerebral white matter investigated by diffusion-tensor imaging. PLoS One (2011) 1.30
Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord (2005) 1.27
Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res (2007) 1.25
Recognition of the tumor suppressor protein p53 and other protein targets by the calcium-binding protein S100B. Biochim Biophys Acta (2006) 1.24
Serum markers support disease-specific glial pathology in major depression. J Affect Disord (2008) 1.18
Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides. Neuropsychopharmacology (2011) 1.14
Stimulation of astroglial 5-HT1A receptors releases the serotonergic growth factor, protein S-100, and alters astroglial morphology. Brain Res (1990) 1.12
Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry (2004) 1.08
S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology (2009) 1.06
Cerebrovascular disease and late-life depression. Am J Geriatr Psychiatry (2005) 1.06
Neurovascular coupling is impaired in cerebral microangiopathy--An event-related Stroop study. Neuroimage (2006) 1.06
Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry (2009) 1.05
Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol (2011) 1.03
A putative functional role for oligodendrocytes in mood regulation. Transl Psychiatry (2012) 1.02
Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry (2006) 1.02
Autocrine S100B effects on astrocytes are mediated via RAGE. J Neuroimmunol (2007) 1.01
S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: Clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience (2004) 1.01
Immunocontent and secretion of S100B in astrocyte cultures from different brain regions in relation to morphology. FEBS Lett (2000) 1.00
S-100beta protects cultured neurons against glutamate- and staurosporine-induced damage and is involved in the antiapoptotic action of the 5 HT(1A)-receptor agonist, Bay x 3702. Brain Res (2000) 1.00
White matter abnormalities in major depression: evidence from post-mortem, neuroimaging and genetic studies. J Affect Disord (2010) 0.99
S100B is increased in mood disorders and may be reduced by antidepressive treatment. Neuroreport (2002) 0.99
Differential regulation of neurotrophin S100B and BDNF in two rat models of depression. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.99
Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis. Psychiatry Res (2009) 0.99
Spontaneous slow hemodynamic oscillations are impaired in cerebral microangiopathy. J Cereb Blood Flow Metab (2005) 0.97
The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets (2009) 0.97
Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - a combined serum, gene expression and MRI study. PLoS One (2012) 0.97
Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus. Neuroreport (2003) 0.96
Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res (2003) 0.95
Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.95
S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol (2003) 0.93
Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatry Neurol (2010) 0.93
Haloperidol and clozapine decrease S100B release from glial cells. Neuroscience (2010) 0.93
S100B in schizophrenic psychosis. Int Rev Neurobiol (2004) 0.93
No evident neuronal damage after electroconvulsive therapy. Psychiatry Res (2000) 0.93
Glia as a putative target for antidepressant treatments. J Affect Disord (2003) 0.92
A novel, rapid, quantitative cell-counting method reveals oligodendroglial reduction in the frontopolar cortex in major depressive disorder. Mol Psychiatry (2011) 0.92
S100B modulates IL-6 release and cytotoxicity from hypothermic brain cells and inhibits hypothermia-induced axonal outgrowth. Neurosci Res (2007) 0.91
Neurotrophic factor S100 beta in major depression. Neuropsychobiology (2001) 0.90
Localization of 5-HT1A receptors to astroglial cells in adult rats: implications for neuronal-glial interactions and psychoactive drug mechanism of action. Synapse (1993) 0.89
Cerebrovascular diseases and depression: epidemiology, mechanisms and treatment. Panminerva Med (2012) 0.88
Astrocytes enhance radical defence in capillary endothelial cells constituting the blood-brain barrier. FEBS Lett (1999) 0.88
The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology (Berl) (2004) 0.87
Long lasting sex-specific effects upon behavior and S100b levels after maternal separation and exposure to a model of post-traumatic stress disorder in rats. Brain Res (2007) 0.87
Neuropathological substrates and structural changes in late-life depression: the impact of vascular burden. Acta Neuropathol (2012) 0.86
Identifying the neural correlates of executive functions in early cerebral microangiopathy: a combined VBM and DTI study. J Cereb Blood Flow Metab (2012) 0.86
Morphometric changes in early- and late-life major depressive disorder: evidence from postmortem studies. Int Psychogeriatr (2009) 0.86
Effects of ethanol and 5-HT1A agonists on astroglial S100B. Brain Res Dev Brain Res (2002) 0.85
Regionally specific changes in levels of cortical S100beta in bipolar 1 disorder but not schizophrenia. Aust N Z J Psychiatry (2006) 0.85
Overweight and obesity are associated with neuronal injury in the human cerebellum and hippocampus in young adults: a combined MRI, serum marker and gene expression study. Transl Psychiatry (2012) 0.85
Relation between electroconvulsive therapy, cognitive side effects, neuron specific enolase, and protein S-100. J Neurol Neurosurg Psychiatry (2001) 0.84
Candidate gene analysis of 21q22: support for S100B as a susceptibility gene for bipolar affective disorder with psychosis. Am J Med Genet B Neuropsychiatr Genet (2007) 0.84
Glial pathology is modified by age in mood disorders--a systematic meta-analysis of serum S100B in vivo studies. J Affect Disord (2010) 0.84
Age-related increase in the number of oligodendrocytes is dysregulated in schizophrenia and mood disorders. Schizophr Res Treatment (2011) 0.84
P11 expression and PET in bipolar disorders. J Psychiatr Res (2011) 0.83
The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression. J Neural Transm (Vienna) (2008) 0.82
Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol (2014) 2.36
Glutamatergic and resting-state functional connectivity correlates of severity in major depression - the role of pregenual anterior cingulate cortex and anterior insula. Front Syst Neurosci (2010) 1.54
Reduced serotonin-1A receptor binding in social anxiety disorder. Biol Psychiatry (2006) 1.46
Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia. J Psychiatr Res (2009) 1.40
The immune theory of psychiatric diseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol (2012) 1.33
Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights (2010) 1.30
Neuroarchitecture of verbal and tonal working memory in nonmusicians and musicians. Hum Brain Mapp (2011) 1.26
Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry (2009) 1.25
Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia. PLoS One (2011) 1.24
Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother (2009) 1.24
Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage (2009) 1.23
Investigating structural brain changes of dehydration using voxel-based morphometry. PLoS One (2012) 1.22
Age correction in dementia--matching to a healthy brain. PLoS One (2011) 1.22
Diffusion tensor imaging of frontal lobe white matter tracts in schizophrenia. Ann Gen Psychiatry (2006) 1.13
Executive deficits are related to the inferior frontal junction in early dementia. Brain (2011) 1.09
Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J Alzheimers Dis (2011) 1.08
Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology (2011) 1.07
Heart failure--an identified but largely ignored source of errors in postmortem brain volume studies. J Card Fail (2013) 1.06
Meta-analysis based SVM classification enables accurate detection of Alzheimer's disease across different clinical centers using FDG-PET and MRI. Psychiatry Res (2012) 1.04
Deep-brain stimulation for Parkinson's disease. N Engl J Med (2013) 1.03
Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol (2004) 1.02
Preferential networks of the mediodorsal nucleus and centromedian-parafascicular complex of the thalamus--a DTI tractography study. Hum Brain Mapp (2011) 1.01
Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations? Brain Behav Immun (2012) 1.01
The role of hippocampus dysfunction in deficient memory encoding and positive symptoms in schizophrenia. Psychiatry Res (2010) 0.99
Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry (2011) 0.98
Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - a combined serum, gene expression and MRI study. PLoS One (2012) 0.97
Seroprevalence of N-methyl-D-aspartate glutamate receptor (NMDA-R) autoantibodies in aging subjects without neuropsychiatric disorders and in dementia patients. Eur Arch Psychiatry Clin Neurosci (2014) 0.97
Deep brain stimulation of the nucleus accumbens for the treatment of addiction. Ann N Y Acad Sci (2012) 0.96
Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease. Neuroimage Clin (2013) 0.96
A morphometric analysis of the septal nuclei in schizophrenia and affective disorders: reduced neuronal density in the lateral septal nucleus in bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2010) 0.93
Mood disorders are glial disorders: evidence from in vivo studies. Cardiovasc Psychiatry Neurol (2010) 0.93
Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One (2013) 0.93
Top-down and bottom-up contributions to understanding sentences describing objects in motion. Front Psychol (2010) 0.92
Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol (2009) 0.92
Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: a potential link to impaired growth factor signaling and energy homeostasis. Eur Arch Psychiatry Clin Neurosci (2011) 0.91
Suicide and depression in the quantitative analysis of glutamic acid decarboxylase-Immunoreactive neuropil. J Affect Disord (2008) 0.91
Differences between unipolar and bipolar I depression in the quantitative analysis of glutamic acid decarboxylase-immunoreactive neuropil. Eur Arch Psychiatry Clin Neurosci (2012) 0.90
Hippocampal CA1 deformity is related to symptom severity and antipsychotic dosage in schizophrenia. Brain (2013) 0.90
Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl) (2007) 0.89
S100B-immunopositive astrocytes and oligodendrocytes in the hippocampus are differentially afflicted in unipolar and bipolar depression: a postmortem study. J Psychiatr Res (2013) 0.89
Levodopa increases functional connectivity in the cerebellum and brainstem in Parkinson's disease. Brain (2013) 0.89
Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses? Eur Arch Psychiatry Clin Neurosci (2014) 0.88
Integration of ultra-high field MRI and histology for connectome based research of brain disorders. Front Neuroanat (2013) 0.88
Generative FDG-PET and MRI model of aging and disease progression in Alzheimer's disease. PLoS Comput Biol (2013) 0.88
Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study. Ann N Y Acad Sci (2007) 0.88
Action prediction in younger versus older adults: neural correlates of motor familiarity. PLoS One (2013) 0.88
Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia. World J Biol Psychiatry (2010) 0.87
Dissociating behavioral disorders in early dementia-An FDG-PET study. Psychiatry Res (2011) 0.87
Ribosomal DNA transcription in the dorsal raphe nucleus is increased in residual but not in paranoid schizophrenia. Eur Arch Psychiatry Clin Neurosci (2014) 0.87
Neural correlates of the DemTect in Alzheimer's disease and frontotemporal lobar degeneration - A combined MRI & FDG-PET study. Neuroimage Clin (2013) 0.86
Menstrual cycle phase modulates emotional conflict processing in women with and without premenstrual syndrome (PMS)--a pilot study. PLoS One (2013) 0.86
Identifying the neural correlates of executive functions in early cerebral microangiopathy: a combined VBM and DTI study. J Cereb Blood Flow Metab (2012) 0.86
The subthalamic microlesion story in Parkinson's disease: electrode insertion-related motor improvement with relative cortico-subcortical hypoactivation in fMRI. PLoS One (2012) 0.85
Glial pathology is modified by age in mood disorders--a systematic meta-analysis of serum S100B in vivo studies. J Affect Disord (2010) 0.84
Increased nuclear Olig1-expression in the pregenual anterior cingulate white matter of patients with major depression: a regenerative attempt to compensate oligodendrocyte loss? J Psychiatr Res (2013) 0.84
Molecular sex differences in human serum. PLoS One (2012) 0.83
The functional architecture of S1 during touch observation described with 7 T fMRI. Brain Struct Funct (2013) 0.83
Distinct structural alterations independently contributing to working memory deficits and symptomatology in paranoid schizophrenia. Cortex (2012) 0.82
Hyperstable regulation of vigilance in patients with major depressive disorder. World J Biol Psychiatry (2011) 0.82
Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease. Neurodegener Dis (2010) 0.82
Demonstration of disturbed activity of the lateral amygdaloid nucleus projection neurons in depressed patients by the AgNOR staining method. J Affect Disord (2010) 0.82
Tyrosine hydroxylase immunoreactivity in the locus coeruleus is elevated in violent suicidal depressive patients. Eur Arch Psychiatry Clin Neurosci (2008) 0.82
The volumes of the fornix in schizophrenia and affective disorders: a post-mortem study. Psychiatry Res (2008) 0.82
Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine. Eur Neuropsychopharmacol (2006) 0.82
Differential regional and cellular distribution of TFF3 peptide in the human brain. Amino Acids (2015) 0.81
Increased density of prohibitin-immunoreactive oligodendrocytes in the dorsolateral prefrontal white matter of subjects with schizophrenia suggests extraneuronal roles for the protein in the disease. Neuromolecular Med (2012) 0.81
Judging roughness by sight--a 7-Tesla fMRI study on responsivity of the primary somatosensory cortex during observed touch of self and others. Hum Brain Mapp (2012) 0.81
Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains. Age (Dordr) (2008) 0.81
A software tool for interactive exploration of intrinsic functional connectivity opens new perspectives for brain surgery. Acta Neurochir (Wien) (2011) 0.81
A postmortem assessment of mammillary body volume, neuronal number and densities, and fornix volume in subjects with mood disorders. Eur Arch Psychiatry Clin Neurosci (2012) 0.80
Agmatinase, an inactivator of the putative endogenous antidepressant agmatine, is strongly upregulated in hippocampal interneurons of subjects with mood disorders. Neuropharmacology (2011) 0.80
Reduction of gyrification index in the cerebellar vermis in schizophrenia: a post-mortem study. World J Biol Psychiatry (2011) 0.80
Regional and cellular distribution patterns of insulin-degrading enzyme in the adult human brain and pituitary. J Chem Neuroanat (2007) 0.80
Abnormal activity in the precuneus during time perception in Parkinson's disease: an fMRI study. PLoS One (2012) 0.80
Disruption of glutamate-glutamine-GABA cycle significantly impacts on suicidal behaviour: survey of the literature and own findings on glutamine synthetase. CNS Neurol Disord Drug Targets (2013) 0.80
Differential distribution of Y-box-binding protein 1 and cold shock domain protein A in developing and adult human brain. Brain Struct Funct (2014) 0.79
The human oligodendrocyte proteome. Proteomics (2013) 0.79
Accounting for movement increases sensitivity in detecting brain activity in Parkinson's disease. PLoS One (2012) 0.79
Abdominal fat distribution and its relationship to brain changes: the differential effects of age on cerebellar structure and function: a cross-sectional, exploratory study. BMJ Open (2013) 0.79
Auditory stroop and absolute pitch: an fMRI study. Hum Brain Mapp (2012) 0.79
Disease severity is correlated to tract specific changes of fractional anisotropy in MD and CM thalamus--a DTI study in major depressive disorder. J Affect Disord (2013) 0.79
Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. Am J Geriatr Psychiatry (2011) 0.79
Demonstration of decreased activity of dorsal raphe nucleus neurons in depressed suicidal patients by the AgNOR staining method. J Affect Disord (2008) 0.79
Increased density of GAD65/67 immunoreactive neurons in the posterior subiculum and parahippocampal gyrus in treated patients with chronic schizophrenia. World J Biol Psychiatry (2011) 0.78
Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy. CNS Neurol Disord Drug Targets (2011) 0.78
Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia. Brain Res (2009) 0.78
Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study. Curr Med Res Opin (2005) 0.78
Age-related increase of VGF-expression in T lymphocytes. Aging (Albany NY) (2014) 0.78
ZNF804A protein is widely expressed in human brain neurons: possible implications on normal brain structure and pathomorphologic changes in schizophrenia. Schizophr Bull (2014) 0.78
Learning by doing? The effect of gestures on implicit retrieval of newly acquired words. Cortex (2012) 0.78
Volumetric analysis of the hypothalamus, amygdala and hippocampus in non-suicidal and suicidal mood disorder patients--a post-mortem study. CNS Neurol Disord Drug Targets (2013) 0.77
Demonstration of disturbed activity of external globus pallidus projecting neurons in depressed patients by the AgNOR staining method. J Affect Disord (2009) 0.77
Demonstration of disturbed activity of orbitofrontal pyramidal neurons in depressed patients by the AgNOR staining method. J Affect Disord (2009) 0.77
Nardilysin, ADAM10, and Alzheimer's disease: of mice and men. Neurobiol Aging (2013) 0.77
Ribosomal DNA transcription in the anterior cingulate cortex is decreased in unipolar but not bipolar I depression. Psychiatry Res (2013) 0.77
Stereological investigation of the posterior hippocampus in affective disorders. J Neural Transm (Vienna) (2014) 0.77